BlossomHill Therapeutics shares exploded higher today following the presentation of positive Phase 1/2 SOLARA trial data at the IASLC 2026 World Conference on Lung Cancer. The data revealed that the OMNI-EGFR inhibitor BH-30643 achieved a 45% objective response rate and an 88% disease control rate in patients with EGFR C797S-positive non-small cell lung cancer, a difficult-to-treat population currently lacking approved targeted therapies. While the stock saw modest gains during the premarket session on September 15 following the initial release of these results, the momentum accelerated throughout the regular trading session as investors digested the clinical significance of the findings and the company's upcoming end-of-Phase I meeting with the FDA.